Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer, accounting for approximately 85% of all lung cancer cases. The NSCLC treatment market is rapidly evolving, driven by advancements in immunotherapy, targeted therapies, and precision medicine. In 2023, the NSCLC treatment market was valued at around USD 19.38 billion, and with an […]
